Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia 21-09-2024, 15:15

Meltwater unveils their digital-first brand campaign, Guesswork Doesn’t Work, to demonstrate the importance of data-driven decisions 10-04-2024, 23:00

FBLA Conference Registration Opens, Brings Thousands of 2-03-2023, 01:18